Dexlansoprazole Capsule, Delayed Release
Product Images NDC 62332-824

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dexlansoprazole (NDC 62332-824). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsules (Dexlansoprazole 30 mg Capsule)

Dexlansoprazole Delayed-Release Capsules 30 mg label shows NDC 62332-823-30, containing 30 capsules. It highlights storage instructions, child-resistant packaging, and dispensing requirements. Labeler is Alembic Pharmaceuticals Inc. with manufacturing in India and USA. Barcode and coding area details are included.*

FDA Label Image

30 Capsules (Dexlansoprazole 60 mg Capsule)

Dexlansoprazole Delayed-Release Capsules 60 mg label for a 30-capsule bottle. The label includes dosage information stating each capsule contains 60 mg of dexlansoprazole as enteric-coated pellets. It highlights storage instructions and manufacturer details: Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, Inc., USA. The label also features a barcode, NDC 62332-824-30, and a note for pharmacists to dispense the accompanying Medication Guide.*

FDA Label Image

Dexlansoprazole-fig1.jpg (Dexlansoprazole Fig1)

A plasma concentration versus time graph showing pharmacokinetic profiles of Dexlansoprazole 30 mg and 60 mg delayed-release capsules. The y-axis measures plasma concentration in ng/mL, and the x-axis shows time in hours up to 24 hours. Two curves illustrate plasma levels over time for each dosage strength, with the 60 mg dose showing higher plasma concentrations compared to the 30 mg dose.*

FDA Label Image

Dexlansoprazole-str.jpg (Dexlansoprazole Str)

Chemical structure of dexlansoprazole active ingredient, showing its molecular arrangement including aromatic rings, sulfoxide group, and trifluoroethoxy substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.